Harmony Biosciences grants 212,241 options to COO
Harmony Biosciences Holdings, Inc. reported that Chief Operating Officer Peter Anastasiou received a grant of stock options covering 212,241 shares of common stock.
Rhea-AI Filing Summary
Harmony Biosciences Holdings, Inc. reported that Chief Operating Officer Peter Anastasiou received a grant of stock options covering 212,241 shares of common stock. The options have an exercise price of $27.74 per share and expire on April 2, 2036.
According to the grant terms, 25% of the underlying shares vest on April 2, 2027, with the remaining options vesting on a quarterly basis until the fourth anniversary of the grant date, contingent on his continued service with the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 212,241 shares
Grant/Award
1 txn
Insider
Anastasiou Peter
Role
CHIEF OPERATING OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 212,241 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option — 212,241 contracts (Direct)
Footnotes (1)
- F1. The stock option vests with respect to 25% of the underlying shares on April 2, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Key Figures
Option grant size: 212,241 options
Exercise price: $27.74 per share
Expiration date: April 2, 2036
+1 more
4 metrics
Option grant size
212,241 options
Stock option award to COO Peter Anastasiou
Exercise price
$27.74 per share
Exercise price for granted stock options
Expiration date
April 2, 2036
Option term end date
Initial vesting date
April 2, 2027
25% of options vest on this date
Key Terms
Stock Option, exercise price, grant date, vesting
4 terms
Stock Option financial
"The stock option vests with respect to 25% of the underlying shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price": "27.7400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
grant date financial
"until the fourth anniversary of the grant date, subject to the Reporting Person's continued service"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
vesting financial
"with the remaining shares vesting ratably on a quarterly basis thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Harmony Biosciences (HRMY) report for Peter Anastasiou?
Harmony Biosciences reported that COO Peter Anastasiou received a grant of stock options for 212,241 shares of common stock. These options were awarded as a compensation-related acquisition rather than an open-market purchase or sale of existing Harmony Biosciences shares.
What are the key terms of Peter Anastasiou’s Harmony Biosciences (HRMY) stock options?
The stock options cover 212,241 underlying shares of Harmony Biosciences common stock at an exercise price of $27.74 per share. They expire on April 2, 2036, giving the executive a long-dated incentive aligned with the company’s future share price performance.
How do the Harmony Biosciences (HRMY) options granted to Peter Anastasiou vest?
The options vest over time. Twenty-five percent of the underlying shares vest on April 2, 2027. The remaining options then vest ratably on a quarterly basis until the fourth anniversary of the grant date, provided he continues his service with Harmony Biosciences.
Is Peter Anastasiou’s Harmony Biosciences (HRMY) option grant an open-market buy or sale?
The transaction is a grant or award of stock options, not an open-market buy or sale. It represents a compensation-related acquisition of derivative securities, giving the COO the right to purchase Harmony Biosciences common stock at a set exercise price in the future.
How many Harmony Biosciences (HRMY) options does Peter Anastasiou hold after this grant?
Following this grant, Peter Anastasiou holds 212,241 stock options directly, according to the filing. Each option is exercisable for one share of Harmony Biosciences common stock, subject to the specified vesting schedule and the long-term expiration date in 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
